GeneOne Life Science진원생명과학
011000 · KOSPI · ₩011000 · 진원생명과학
₩2,670 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩23B | ₩36B | ₩40B | ₩49B | ₩39B |
| Cost of sales | ₩38B | ₩47B | ₩48B | ₩39B | ₩30B |
| Gross profit | −₩15B | −₩11B | −₩7.8B | ₩9.3B | ₩8.8B |
| Operating income | −₩44B | −₩43B | −₩48B | −₩40B | −₩28B |
| Net income | −₩52B | −₩49B | −₩78B | −₩38B | −₩16B |
| Net income to shareholders | −₩52B | −₩49B | −₩78B | −₩38B | −₩16B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩119B | ₩151B | ₩151B | ₩223B | ₩249B |
| Current assets | ₩19B | ₩29B | ₩35B | ₩73B | ₩133B |
| Cash and equivalents | ₩1.3B | ₩1.2B | ₩9.1B | ₩13B | ₩22B |
| Total liabilities | ₩78B | ₩66B | ₩40B | ₩41B | ₩44B |
| Current liabilities | ₩54B | ₩43B | ₩23B | ₩34B | ₩34B |
| Borrowings | ₩1.9B | ₩3.4B | ₩8.7B | ₩12B | ₩9.8B |
| Total equity | ₩41B | ₩86B | ₩111B | ₩181B | ₩205B |
| Shareholders' equity | ₩41B | ₩86B | ₩111B | ₩181B | ₩205B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩17B | −₩16B | −₩22B | −₩24B | −₩4.8B |
| Capital spending | ₩24M | ₩3.3B | ₩5.6B | ₩45B | ₩82B |
| Free cash flow | −₩17B | −₩19B | −₩27B | −₩69B | −₩87B |
Consolidated where available. Amounts in won.
Also known as: GeneOne Life Science / 진원생명과학 / 011000 / KRX:011000
Source: KRX statistical information